Towards integrating positron emission tomography for work-up of patients with Sjögren's syndrome and associated lymphomas

Autoimmunity Reviews

Volumn 13, Issue 3, 2014, Pages 327-329

  Ziakas, Panayiotis D ^a,b   Poulou, Loukia S ^c   Thanos, Loukas ^c  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

Biopsy; Fluorodeoxyglucose; Lymphoma; PET; Sj gren's syndrome; Volumetry

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER RADIOTHERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; HYPERGAMMAGLOBULINEMIA; INTERSTITIAL LUNG DISEASE; LARGE CELL LYMPHOMA; LETTER; LYMPHOMA; MARGINAL ZONE LYMPHOMA; MINIMAL RESIDUAL DISEASE; MINOR SALIVA GLAND; OPEN LUNG BIOPSY; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; STANDARDIZED MORTALITY RATIO;

BIOPSY; FLUORODEOXYGLUCOSE; LYMPHOMA; PET; SJÖGREN'S SYNDROME; VOLUMETRY;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; SJOGREN'S SYNDROME; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84891739841     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.11.002     Document Type: Letter

References (29)

1. Baimpa E., Dahabreh I.J., Voulgarelis M., Moutsopoulos H.M. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009, 88(5):284-293.
2. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005, 165(20):2337-2344.
3. Voulgarelis M., Ziakas P.D., Papageorgiou A., Baimpa E., Tzioufas A.G., Moutsopoulos H.M. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore) 2012, 91(1):1-9.
4. Cheson B.D., Pfistner B., Juweid M.E., Gascoyne R.D., Specht L., Horning S.J., et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25(5):579-586.
5. Ziakas P.D., Poulou L.S., Voulgarelis M., Thanos L. The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies. Leuk Lymphoma 2012, 53(11):2166-2174.
6. Poulou L.S., Thanos L., Ziakas P.D. Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials. Eur J Nucl Med Mol Imaging 2010, 37(1):156-162.
7. Meignan M., Barrington S., Itti E., Gallamini A., Haioun C., Polliack A. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma 2013, [Epub ahead of print].
8. Poulou L.S., Ziakas P.D., Ziogas D.C., Doxani C., Xyla V., Vakrinos G., et al. FDG-PET for detecting local tumor recurrence of ablated liver metastases: a diagnostic meta-analysis. Biomarkers 2012, 17(6):532-538.
9. Herrmann K., Benz M.R., Krause B.J., Pomykala K.L., Buck A.K., Czernin J. (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go. Q J Nucl Med Mol Imaging 2011, 55(6):620-632.
10. Mac Manus M.P., Ryan G., Lau E., Wirth A., Hicks R.J. Positron emission tomography of stage IV mucosa-associated lymphoid tissue lymphoma confined to the four major salivary glands. Australas Radiol 2007, 51(1):68-70.
11. Jadvar H., Bonyadlou S., Iagaru A., Colletti P.M. FDG PET-CT demonstration of Sjogren's sialoadenitis. Clin Nucl Med 2005, 30(10):698-699.
12. Shih W.J., Ghesani N., Hongming Z., Alavi A., Schusper S., Mozley D. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med 2002, 27(2):142-143.
13. Cohen C., Mekinian A., Uzunhan Y., Fauchais A.L., Dhote R., Pop G., et al. 18F-fluorodeoxyglucose positron emission tomography/computer tomography as an objective tool for assessing disease activity in Sjögren's syndrome. Autoimmun Rev 2013, 12(11):1109-1114.
14. Seror R., Ravaud P., Bowman S.J., Baron G., Tzioufas A., Theander E., et al. EULAR Sjögren's Task Force. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010, 69(6):1103-1109.
15. Poulou L.S., Ziakas P., Papageorgiou A., Papanikolaou M., Kapsogeorgou E., Tzioufas A., et al. FDG-PET/CT in the post-therapy evaluation of salivary gland lymphomas in Sjogren's syndrome: a prospective study. European Congress of Radiology 2013, [C-0355 d].
16. Zincirkeser S., Sahin E., Halac M., Sager S. Standardized uptake values of normal organs on 18F-fluorodeoxyglucose positron emission tomography and computed tomography imaging. J Int Med Res 2007, 35(2):231-236.
17. Nakamoto Y., Tatsumi M., Hammoud D., Cohade C., Osman M.M., Wahl R.L. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005, 234(3):879-885.
18. Weiler-Sagie M., Bushelev O., Epelbaum R., Dann E.J., Haim N., Avivi I., et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010, 51(1):25-30.
19. Perry C., Herishanu Y., Metzer U., Bairey O., Ruchlemer R., Trejo L., et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol 2007, 79(3):205-209.
20. Karam M., Novak L., Cyriac J., Ali A., Nazeer T., Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006, 107(1):175-183.
21. Hoffmann M., Wöhrer S., Becherer A., Chott A., Streubel B., Kletter K., et al. 18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol 2006, 17(12):1761-1765.
22. Medbery R., Yousem D.M., Needham M.F., Kligerman M.M. Variation in parotid gland size, configuration, and anatomic relations. Radiother Oncol 2000, 54(1):87-89.
23. Teshima K., Murakami R., Tomitaka E., Nomura T., Toya R., Hiraki A., et al. Radiation-induced parotid gland changes in oral cancer patients: correlation between parotid volume and saliva production. Jpn J Clin Oncol 2010, 40(1):42-46.
24. Sasanelli M., Itti E., Biggi A., Berriolo-Riedinger A., Cashen A., Tilly H., et al. Prognostic value of pretherapy metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with diffuse large B-cell lymphoma (DLBCL). J Nucl Med (Meet Abstr) 2012, 53:560.
25. Boulesteix M., Touati M., Abraham J., Verbeke S., El Badaoui A., Gourin M.P., et al. FDG-PET/CT Metabolic Tumor Volume: A New Prognostic Marker in Hodgkin Lymphoma?. Blood (ASH Annu Meet Abstr) 2012, 120(21):3632.
26. Casasnovas R.-O., Sasanelli M., Berriolo-Riedinger A., Morschhauser F., Itti E., Huglo D., et al. Baseline Metabolic Tumor Volume Is Predictive of Patient Outcome in Diffuse Large B Cell Lymphoma. ASH Annu Meet Abstr 2012, 120(21):1598.
27. Zhang W.D., Guan Y.B., Li C.X., Huang X.B., Zhang F.J. Pulmonary mucosa-associated lymphoid tissue lymphoma: computed tomography and 18F fluorodeoxyglucose-positron emission tomography/computed tomography imaging findings and follow-up. J Comput Assist Tomogr 2011, 35(5):608-613.
28. Poulou L.S., Tsagouli P., Ziakas P.D., Politi D., Trigidou R., Thanos L. Computed tomography-guided needle aspiration and biopsy of pulmonary lesions: a single-center experience in 1000 patients. Acta Radiol 2013, 54(6):640-645.
29. Poulou L.S., Tsangaridou I., Filippoussis P., Sidiropoulou N., Apostolopoulou S., Thanos L. Feasibility of CT-guided percutaneous needle biopsy in early diagnosis of BOOP. Cardiovasc Intervent Radiol 2008, 31(5):1003-1007.